The evolution of cellular cancer immunotherapy represents a fundamental shift in how medicine harnesses the body's immune system to eliminate malignancies. This comprehensive analysis reveals how engineered immune cells are overcoming traditional treatment limitations through increasingly sophisticated targeting mechanisms. The review examines breakthrough developments in CAR-T cell engineering, tumor-infiltrating lymphocyte therapies, and novel cellular platforms that address the complex challenge of tumor immune evasion. Key mechanistic insights highlight how modified T cells, natural killer cells, and dendritic cell vaccines are being optimized to penetrate solid tumors, persist longer in hostile microenvironments, and maintain cytotoxic function despite immunosuppressive signals. The analysis identifies emerging approaches including allogeneic off-the-shelf therapies, multi-antigen targeting systems, and combination strategies that simultaneously attack cancer cells while reprogramming the tumor microenvironment. From a longevity perspective, these cellular therapies represent more than cancer treatment—they demonstrate the potential for immune system rejuvenation and enhanced surveillance against age-related malignancies. However, significant hurdles remain including manufacturing complexity, severe side effects like cytokine release syndrome, and the substantial cost barriers limiting widespread access. The field appears to be transitioning from proof-of-concept successes in blood cancers toward the far more challenging landscape of solid tumors, where spatial barriers and immunosuppressive conditions continue to limit efficacy. This technological progression suggests we're approaching an era where personalized immune cell engineering could become a cornerstone of precision oncology.